ecallantide (Kalbitor)

Indications

• treatment of acute attacks of hereditary angioedema in patients 16 years of age & older

Dosage

• 30 mg (3 mL) SQ in 3 10 mg (1 mL) injections
• if an attack persists, an additional dose of 30 mg may be administered within a 24 hour period

Adverse effects

• most common (> 3%)
  • headache, nausea, diarrhea, pyrexia, nasopharyngitis. injection site reactions

Mechanism of action

• plasma kallikrein inhibitor

More general terms

• enzyme inhibitor
• biological response modifier